

November 3, 2016

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Press Release for Unaudited Financial Results for the quarter and half year ended September 30, 2016

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Unaudited Financial Results for the Quarter and half year ended September 30, 2016.

You are requested to take note of the above.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited



Rajat Kalra

Company Secretary & Legal Head

Encl: As above

Dr. Lal PathLabs Limited records growth of 21.5% in Q2 FY2016-17

New Delhi, India, Nov 3, 2016 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended Sept 30, 2016

Consolidated Performance Highlights: Q2FY2016-17 vs. Q2FY2015-16

- Operating Revenue increased by 21.5% Y-o-Y to Rs. 2,622 million vs Rs 2,157 million in the previous year. Underlying volume growth is 13.6%. FH’17 revenue grew at 19.7% to Rs 4,850 million with underlying volume growth at 14.3%
- Normalised EBITDA increased by 37.7% Y-o-Y to Rs.798 million from Rs 580 million in the same quarter last year, after adjusting for ESOP provisions in Previous year financials. FH’17 EBITDA at Rs 1402 million grew at 28.1%.
- EBITDA Margin was 30.4% for Q2 2016 vs 26.9% in Q2 2015. First half margins as 28.9% vs 27% in Previous year
- Profit after Tax in Q2 increased to Rs. 528 million from Rs 65 million in previous year. FH’17 PAT increased from RS 375 million to Rs 930 million. The numbers are not strictly comparable as previous year had an ESOP charge of Rs 382 million in Q2 and Rs 405 million FH’16.

Financial Overview (Consolidated) in Rs mn

Particulars	SQ FY 17	SQ FY 16	Gr %	6MFY17	6MFY16	Gr %	12M FY16
Revenue	2,621.7	2,157.3	21.5%	4,850.1	4,050.4	19.7%	7,913.2
Total Expenditure	1,823.5	1,794.1	1.6%	3,447.9	3,195.1	7.9%	5,816.0
EBITDA	798.2	363.2		1,402.2	855.3		2,097.2
ESOP	-	216.6		-	239.1		(34.7)
EBITDA excl ESOP	798.2	579.8	37.7%	1,402.2	1,094.4	28.1%	2,062.5
Margins	30.4%	26.9%		28.9%	27.0%		26.1%
Other income incl interest	62.7	50.7	23.7%	122.8	91.8	33.8%	197.7
PBT	793.8	174.8	354.1%	1,393.1	643.1	116.6%	2,007.2
Margins	30.3%	8.1%		28.7%	15.9%		10.0%
PAT	528.5	64.9	714.3%	930.2	374.7	148.3%	1,332.3
Margins	20.2%	3.0%		19.2%	9.3%		16.8%
EPS per share of Rs 10 (Diluted)	6.30	0.75		11.08	4.47		15.98

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.



Dr. Lal PathLabs has built a national, “hub and spoke” network that includes its National Reference Laboratory in New Delhi, 171 other clinical laboratories, 1,559 patient service centers and nearly 5,000 pickup points as of March 31, 2016. Their customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Dilip Bidani
Dr. Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Aparna Agarwal
Adfactors PR

+919811177405
aparna.agarwal@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

Dr. Lal Pathlabs Limited

12th Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com